TETRAVALENT CD47-ANTIBODY CONSTANT REGION FUSION PROTEIN FOR USE IN THERAPY

The present invention relates to soluble SIRPa binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble SIRPa binding protein comprising a complex of two heterodimers, wherein each heterodimer essentially consists of: (i) a first monovalent single chain polypeptide comprising a first SIRPa binding domain fused at the N-terminal part of a heavy chain constant region of an antibody; and, (ii) a second monovalent single chain polypeptide comprising a second SIRPa binding domain fused at the N-terminal part of a CL light chain constant region of an antibody. The invention further relates to soluble SIRPa-binding antibody-like protein as shown in Figure 1.